S&P Futures
4,003.75 -16.00 (-0.40%) Dow Futures
32,063.00 -57.00 (-0.18%) Nasdaq Futures
12,304.75 -78.00 (-0.63%) Russell 2000 Futures
1,781.70 -7.80 (-0.44%) Crude Oil
109.93 -0.56 (-0.51%) Gold
1,797.70 -10.50 (-0.58%)
Orchard Therapeutics plc (ORTX)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.4225 |
| Open | 0.4300 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 1100 |
| Day's Range | 0.4200 - 0.4800 |
| 52 Week Range | 0.4100 - 5.6900 |
| Volume | |
| Avg. Volume | 593,073 |
| Market Cap | 59.499M |
| Beta (5Y Monthly) | 1.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2120 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.31 |
- GlobeNewswire
Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven upcoming presentations at ASGCT highlight application of HSC approach including clinical and research programs Cash and investments of approximately $200M provide runway into 2024 BOSTON and LO
- GlobeNewswire
Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond
BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19 in Washington, D.C. Featured presentations include updated results on the OTL-203 clinical program for mucopolysaccharidosis type I Hurler syndrome (MPS-IH), as well as several accepted abstracts highlighting
- GlobeNewswire
Orchard Therapeutics to Webcast Conference Call of First Quarter 2022 Financial Results
BOSTON and LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 12, 2022, at 8:00 a.m. ET to review business updates and its first quarter 2022 financial results. A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at www.orchard-tx.com. The conference call can be accessed by dialing +1 (
